サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1350667

医薬品グレードの炭酸リチウムの世界市場：用途別、純度別、地域別-2028年までの予測

Pharmaceutical Grade Lithium Carbonate Market by Application (Extended Release, Immediate Release), Purity (99%, Above 99%), and Region (Asia Pacific, Europe, North America, Middle East & Africa, and South America) - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 144 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
医薬品グレードの炭酸リチウムの世界市場：用途別、純度別、地域別-2028年までの予測
出版日: 2023年09月13日
発行: MarketsandMarkets
ページ情報: 英文 144 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

医薬品グレードの炭酸リチウムの市場規模は、2023年の1億4,100万米ドルから2028年には1億6,600万米ドルに成長し、2023年から2028年までのCAGRは3.3%と予測されています。

炭酸リチウムは、双極性障害などの精神疾患の治療における気分安定剤として一般的に使用されています。メンタルヘルスに対する意識が高まり、治療を求める人が増えるにつれて、医薬品グレードの炭酸リチウムの需要は増加すると予想されます。

医薬品グレードの炭酸リチウム徐放薬は、長期間にわたって徐々に薬物を放出します。これにより、血流中の薬物濃度がより一定になり、即時放出薬で起こりうる変動が減少します。このように体内の薬物濃度が安定することで、治療成績が向上し、副作用が軽減されます。また、不安やその他の精神疾患に苦しむ患者の多くは、長期的な治療を必要としています。徐放性製剤は、長期間にわたって効果が持続するため、頻繁な投与の必要性を減らし、患者のQOLを向上させることができるため、これらの疾患には特に有益です。

北米ではメンタルヘルスに対する意識が高まっており、双極性障害のような疾患の認知・診断が進んでいます。炭酸リチウムは双極性障害の一般的な治療薬であり、治療を求める人が増えるにつれて、医薬品グレードの炭酸リチウムの需要が増加すると予想されます。北米はヘルスケアのインフラが発達しており、医薬品の効果的な流通と入手が可能です。医薬品グレードの炭酸リチウムを含むヘルスケアサービスと医薬品が入手可能であることが、市場の成長に寄与しています。

当レポートでは、世界の医薬品グレードの炭酸リチウム市場について調査し、用途別、純度別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 業界の動向

  • 生態系マッピング
  • バリューチェーン分析
  • 技術分析
  • 規制状況
  • 2023年～2024年の主要な会議とイベント
  • 特許分析
  • 主要な利害関係者と購入基準
  • ケーススタディ分析
  • ポーターのファイブフォース分析
  • 貿易分析
  • 価格分析

第7章 医薬品グレードの炭酸リチウム市場、純度別

  • イントロダクション
  • 99.0%
  • 99%超

第8章 医薬品グレードの炭酸リチウム市場、用途別

  • イントロダクション
  • 即放
  • 徐放

第9章 医薬品グレードの炭酸リチウム、地域別

  • イントロダクション
  • アジア太平洋
  • 北米
  • 欧州
  • 中東・アフリカ
  • 南米

第10章 競合情勢

  • イントロダクション
  • 主要参入企業が採用した戦略
  • 市場シェア分析
  • 企業の製品フットプリント分析
  • 企業評価マトリックス（Tier 1）
  • 競合ベンチマーキング
  • スタートアップ/中小企業の評価マトリックス
  • 競合シナリオ

第11章 企業プロファイル

  • 主要参入企業
    • LIVENT CORPORATION
    • ALBEMARLE CORPORATION
    • JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.
    • AMERICAN ELEMENTS
    • GLOBE QUIMICA
    • JIANGSU NHWA PHARMACEUTICAL CO., LTD.
    • PANCHSHEEL ORGANICS LTD（POLTD）
    • BLANVER
  • その他の企業
    • ZHENJIANG POWORKS CO., LTD.
    • AXIOM CHEMICALS PVT. LTD.
    • HUBEI RISON CHEMICAL CO., LTD.
    • PHARMAFFILIATES ANALYTICS AND SYNTHETICS P. LTD.

第12章 付録

目次
Product Code: MM 8781

The pharmaceutical grade lithium carbonate market is projected to grow from USD 141 million in 2023 to USD 166 million by 2028, at a CAGR of 3.3% from 2023 to 2028. Lithium carbonate is commonly used as a mood stabilizer in the treatment of mental conditions such as bipolar disorder. As mental health awareness increases and more people seek treatment, the demand for pharmaceutical grade lithium carbonate is expected to increase.

"By application, extended release segment is expected to be the larger segment during 2023 to 2028."

The pharmaceutical grade lithium carbonate extended release medications release the drug gradually over an extended period of time. This leads to more consistent drug levels in the bloodstream, reducing the fluctuations that can occur with immediate release medications. This steadier concentration of medicine in the body can lead to better therapeutic outcomes and reduced side effects. Also, many patients suffering from anxiety and other mental illness requires long-term treatment. Extended release formulations are particularly beneficial for these conditions because they provide a sustained effect over time, reducing the need for frequent dosing and improving the patient's quality of life.

"By region, North America is expected to be the largest market in 2023, by value."

Mental health awareness has been on the rise in North America, leading to greater recognition and diagnosis of conditions like bipolar disorder. Lithium carbonate is a common treatment for bipolar disorder, and as more individuals seek treatment, the demand for pharmaceutical grade lithium carbonate is expected to increase. North America has a well-developed healthcare infrastructure, which allows for the effective distribution and access to pharmaceuticals. The availability of healthcare services and medications, including pharmaceutical grade lithium carbonate, contributes to market growth.

Profile break-up of primary participants for the report:

  • By Company Type: Tier 1 - 65%, Tier 2 - 20%, and Tier 3 - 15%
  • By Designation: C-level Executives - 25%, Directors - 30%, and Others - 45%
  • By Region: North America - 20%, Europe - 15%, Asia Pacific - 55%, Middle East & Africa - 3%, South America - 7%

The pharmaceutical grade lithium carbonate contactor report is dominated by players, such as Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Quimica (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil), and others.

Research Coverage:

The report defines, segments, and projects the size of the pharmaceutical grade lithium carbonate contactor market based on application, purity, and region. It strategically profiles the key players and comprehensively analyzes their market share and core competencies. It also tracks and analyzes competitive developments, such as product launch, agreement, acquisition, and investments undertaken by them in the market.

Reasons to Buy the Report:

The report is expected to help the market leaders/new entrants in the market by providing them with the closest approximations of revenue numbers of the pharmaceutical grade lithium carbonate contactor market and its segments. This report is also expected to help stakeholders obtain an improved understanding of the competitive landscape of the market, gain insights to improve the position of their businesses and make suitable go-to-market strategies. It also enables stakeholders to understand the pulse of the market and provide them information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising cases of mental illness), restraints (side effects and safety concerns), opportunities (potential for new applications owing to clinical research and innovation), and challenges (stigma and perception of mental health disorder) influencing the growth of the pharmaceutical grade lithium carbonate contactor market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the pharmaceutical grade lithium carbonate contactor market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the pharmaceutical grade lithium carbonate contactor market across varied regions.
  • Market Diversification: Exhaustive information about new products, various production technologies, untapped geographies, recent developments, and investments in the pharmaceutical grade lithium carbonate contactor market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Quimica (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil), among others in the pharmaceutical grade lithium carbonate contactor market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • TABLE 1 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • FIGURE 1 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SEGMENTATION
    • 1.3.1 REGIONS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 UNITS CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
    • 1.7.1 IMPACT OF RECESSION

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Companies participating in primary research
      • 2.1.2.3 Breakdown of primary interviews
  • 2.2 DEMAND-SIDE APPROACH
    • FIGURE 3 MAIN MATRIX CONSIDERED TO CONSTRUCT AND ASSESS DEMAND FOR PHARMACEUTICAL GRADE LITHIUM CARBONATE
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • 2.4 SUPPLY-SIDE APPROACH
    • FIGURE 6 METHODOLOGY FOR SUPPLY-SIDE SIZING OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (1/2)
    • FIGURE 7 METHODOLOGY FOR SUPPLY-SIDE SIZING OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (2/2)
    • 2.4.1 CALCULATIONS FOR SUPPLY-SIDE ANALYSIS
  • 2.5 DATA TRIANGULATION
    • FIGURE 8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DATA TRIANGULATION
  • 2.6 GROWTH FORECAST
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RESEARCH ASSUMPTIONS
  • 2.9 RESEARCH LIMITATIONS
  • 2.10 RISK ANALYSIS
  • 2.11 IMPACT OF RECESSION

3 EXECUTIVE SUMMARY

    • TABLE 2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SNAPSHOT: 2023 VS. 2028
    • FIGURE 9 EXTENDED-RELEASE SEGMENT TO HOLD LARGER MARKET SHARE DURING FORECAST PERIOD
    • FIGURE 10 NORTH AMERICA TO LEAD THE PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET DURING FORECAST PERIOD

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • FIGURE 11 RISE IN CASES OF MENTAL ILLNESS TO DRIVE MARKET
  • 4.2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION
    • FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.3 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION
    • FIGURE 13 EXTENDED-RELEASE SEGMENT TO GROW AT HIGHER CAGR DURING FORECAST PERIOD
  • 4.4 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • FIGURE 14 EXTENDED-RELEASE APPLICATION ACCOUNTS FOR LARGER MARKET SHARE

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising cases of mental illness
    • FIGURE 16 PREVALENCE OF MENTAL DISORDERS ACROSS WHO REGIONS, 2019
        • 5.2.1.1.1 Growing awareness of mental health
        • 5.2.1.1.2 Changes in lifestyle and increase in stress
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Availability of substitutes
      • 5.2.2.2 Side effects and safety concerns
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Potential for new applications owing to clinical research and innovation
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent pharmaceutical standards and regulations
      • 5.2.4.2 Stigma and perception of mental disorders

6 INDUSTRY TRENDS

  • 6.1 ECOSYSTEM MAPPING
    • FIGURE 17 ECOSYSTEM MAP OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • TABLE 3 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: ECOSYSTEM MAPPING
  • 6.2 VALUE CHAIN ANALYSIS
    • FIGURE 18 VALUE CHAIN ANALYSIS OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • 6.2.1 LITHIUM RESOURCE EXTRACTION AND PROCESSING
    • 6.2.2 CONVERSION TO LITHIUM CARBONATE
    • 6.2.3 PURIFICATION AND QUALITY CONTROL
    • 6.2.4 PHARMACEUTICAL FORMULATION AND MANUFACTURING OF PHARMACEUTICAL PRODUCTS
    • 6.2.5 REGULATORY COMPLIANCE AND TESTING
    • 6.2.6 DISTRIBUTION AND SUPPLY CHAIN
    • 6.2.7 PHARMACEUTICAL USE
  • 6.3 TECHNOLOGY ANALYSIS
  • 6.4 REGULATORY LANDSCAPE
    • 6.4.1 REGULATIONS RELATED TO PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • 6.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.5 KEY CONFERENCES AND EVENTS, 2023-2024
    • TABLE 8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: CONFERENCES AND EVENTS, 2023-2024
  • 6.6 PATENT ANALYSIS
    • 6.6.1 INTRODUCTION
    • 6.6.2 METHODOLOGY
    • 6.6.3 DOCUMENT TYPE
    • FIGURE 19 NUMBER OF GRANTED PATENTS, PATENT APPLICATIONS, AND LIMITED PATENTS
    • FIGURE 20 PUBLICATION TRENDS IN LAST 10 YEARS
    • 6.6.4 INSIGHTS
    • FIGURE 21 LEGAL STATUS OF PATENTS
    • 6.6.5 JURISDICTION ANALYSIS
    • FIGURE 22 TOP JURISDICTION, BY DOCUMENT
    • 6.6.6 TOP COMPANIES/APPLICANTS
    • FIGURE 23 COMPANIES/APPLICANTS WITH HIGHEST NUMBER OF PATENTS
    • TABLE 9 PATENTS: OROCOBRE LIMITED
    • TABLE 10 PATENTS: CONTITECH USA INC.
    • TABLE 11 TOP PATENT OWNERS DURING LAST 10 YEARS
  • 6.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 6.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO APPLICATIONS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO APPLICATIONS (%)
    • 6.7.2 BUYING CRITERIA
    • FIGURE 25 KEY BUYING CRITERIA FOR TOP TWO APPLICATIONS
    • TABLE 13 KEY BUYING CRITERIA FOR TOP TWO APPLICATIONS
  • 6.8 CASE STUDY ANALYSIS
    • 6.8.1 OBJECTIVE
    • 6.8.2 DESCRIPTION
    • 6.8.3 METHOD
    • 6.8.4 RESULTS
  • 6.9 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 26 PORTER'S FIVE FORCES ANALYSIS OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
    • TABLE 14 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.9.1 THREAT OF NEW ENTRANTS
    • 6.9.2 THREAT OF SUBSTITUTES
    • 6.9.3 BARGAINING POWER OF BUYERS
    • 6.9.4 BARGAINING POWER OF SUPPLIERS
    • 6.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.10 TRADE ANALYSIS
    • 6.10.1 IMPORT-EXPORT SCENARIO
    • TABLE 15 LITHIUM CARBONATE EXPORT TRADE DATA, 2022
    • TABLE 16 LITHIUM CARBONATE IMPORT TRADE DATA, 2022
  • 6.11 PRICING ANALYSIS
    • 6.11.1 AVERAGE SELLING PRICE FOR PHARMACEUTICAL GRADE LITHIUM CARBONATE, BY REGION IN 2022
    • FIGURE 27 AVERAGE SELLING PRICE, BY REGION

7 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY PURITY

  • 7.1 INTRODUCTION
  • 7.2 99.0%
  • 7.3 ABOVE 99%

8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • FIGURE 28 EXTENDED RELEASE TO BE LARGER MARKET SEGMENT DURING FORECAST PERIOD
    • TABLE 17 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 18 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • TABLE 19 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 20 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
  • 8.2 IMMEDIATE RELEASE
    • 8.2.1 IMMEDIATE-RELEASE MEDICINES PROVIDE RAPID RELIEF OF SYMPTOMS
    • TABLE 21 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (TON)
    • TABLE 22 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (TON)
    • TABLE 23 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (USD MILLION)
    • TABLE 24 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (USD MILLION)
  • 8.3 EXTENDED RELEASE
    • 8.3.1 EXTENDED-RELEASE MEDICINES REDUCE RISK OF SIDE EFFECTS
    • TABLE 25 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (TON)
    • TABLE 26 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (TON)
    • TABLE 27 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (USD MILLION)
    • TABLE 28 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (USD MILLION)

9 PHARMACEUTICAL GRADE LITHIUM CARBONATE, BY REGION

  • 9.1 INTRODUCTION
    • FIGURE 29 NORTH AMERICA TO DRIVE PHARMACEUTICAL GRADE LITHIUM CARBONATE DURING FORECAST PERIOD
    • TABLE 29 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (USD MILLION)
    • TABLE 30 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (USD MILLION)
    • TABLE 31 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019-2022 (TON)
    • TABLE 32 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023-2028 (TON)
  • 9.2 ASIA PACIFIC
    • 9.2.1 RECESSION IMPACT
    • FIGURE 30 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE SNAPSHOT
    • TABLE 33 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (TON)
    • TABLE 36 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (TON)
    • TABLE 37 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 40 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.2.2 CHINA
      • 9.2.2.1 Expansion of treatment facilities pertaining to mental disorders to drive market
    • TABLE 41 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 42 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 43 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 44 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.2.3 INDIA
      • 9.2.3.1 Government initiatives for encouraging mental health treatments to drive demand
    • TABLE 45 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 46 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 47 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 48 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.2.4 JAPAN
      • 9.2.4.1 Increasing need for treatment of mental illnesses to drive market
    • TABLE 49 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 50 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 51 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 52 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.2.5 SOUTH KOREA
      • 9.2.5.1 Presence of mental health centers to improve research and increase demand
    • TABLE 53 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 54 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 55 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 56 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.2.6 REST OF ASIA PACIFIC
    • TABLE 57 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 58 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 59 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 60 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
  • 9.3 NORTH AMERICA
    • 9.3.1 RECESSION IMPACT
    • FIGURE 31 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE SNAPSHOT
    • TABLE 61 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (USD MILLION)
    • TABLE 62 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (TON)
    • TABLE 64 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (TON)
    • TABLE 65 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 66 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 68 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.3.2 US
      • 9.3.2.1 Laws pertaining to mental health and disorder treatment to drive demand
    • TABLE 69 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 70 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 71 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 72 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.3.3 CANADA
      • 9.3.3.1 Investment in quality mental health treatment to drive growth
    • TABLE 73 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 74 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 75 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 76 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.3.4 MEXICO
      • 9.3.4.1 Campaigns and educational initiatives to influence growth
    • TABLE 77 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 78 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 79 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 80 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
  • 9.4 EUROPE
    • 9.4.1 RECESSION IMPACT
    • FIGURE 32 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SNAPSHOT
    • TABLE 81 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (USD MILLION)
    • TABLE 82 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (USD MILLION)
    • TABLE 83 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (TON)
    • TABLE 84 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (TON)
    • TABLE 85 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 86 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 87 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 88 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.4.2 GERMANY
      • 9.4.2.1 Well-established healthcare system to drive market
    • TABLE 89 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 90 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 91 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 92 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.4.3 FRANCE
      • 9.4.3.1 Support and initiative from government toward mental health issues to drive demand
    • TABLE 93 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 94 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 95 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 96 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.4.4 UK
      • 9.4.4.1 Growing cases of mental illness to drive demand
    • TABLE 97 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 98 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 99 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 100 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.4.5 REST OF EUROPE
    • TABLE 101 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 102 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 103 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 104 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
  • 9.5 MIDDLE EAST & AFRICA
    • 9.5.1 RECESSION IMPACT
    • TABLE 105 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (USD MILLION)
    • TABLE 106 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (USD MILLION)
    • TABLE 107 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (TON)
    • TABLE 108 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (TON)
    • TABLE 109 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 110 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 111 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 112 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.5.2 SAUDI ARABIA
      • 9.5.2.1 Growing awareness and government support for mental illness to drive demand
    • TABLE 113 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 114 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 115 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 116 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.5.3 UAE
      • 9.5.3.1 Growing investment to improve drug sector to drive demand
    • TABLE 117 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 118 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 119 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 120 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
      • 9.5.3.2 Rest of Middle East & Africa
    • TABLE 121 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 122 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 123 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 124 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
  • 9.6 SOUTH AMERICA
    • 9.6.1 RECESSION IMPACT
    • TABLE 125 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (USD MILLION)
    • TABLE 126 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (USD MILLION)
    • TABLE 127 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019-2022 (TON)
    • TABLE 128 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023-2028 (TON)
    • TABLE 129 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 130 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 131 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 132 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.6.2 BRAZIL
      • 9.6.2.1 Growing efforts to raise awareness about mental health issues to drive market
    • TABLE 133 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 134 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 135 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 136 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)
    • 9.6.3 REST OF SOUTH AMERICA
    • TABLE 137 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (USD MILLION)
    • TABLE 138 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (USD MILLION)
    • TABLE 139 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019-2022 (TON)
    • TABLE 140 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023-2028 (TON)

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS
  • 10.3 MARKET SHARE ANALYSIS
    • 10.3.1 RANKING OF KEY MARKET PLAYERS, 2022
    • FIGURE 33 RANKING OF KEY PLAYERS IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, 2022
    • 10.3.2 MARKET SHARE OF KEY PLAYERS
    • FIGURE 34 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SHARE ANALYSIS
    • TABLE 142 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DEGREE OF COMPETITION
      • 10.3.2.1 Livent Corporation
      • 10.3.2.2 Albemarle Corporation
      • 10.3.2.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
    • 10.3.3 REVENUE ANALYSIS OF TOP PLAYERS
    • FIGURE 35 REVENUE ANALYSIS OF KEY COMPANIES, 2018-2022
  • 10.4 COMPANY PRODUCT FOOTPRINT ANALYSIS
    • FIGURE 36 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPANY FOOTPRINT
    • TABLE 143 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: PURITY FOOTPRINT
    • TABLE 144 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPANY REGION FOOTPRINT
  • 10.5 COMPANY EVALUATION MATRIX (TIER 1)
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 37 COMPANY EVALUATION MATRIX: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (TIER 1 COMPANIES)
  • 10.6 COMPETITIVE BENCHMARKING
    • TABLE 145 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: KEY STARTUPS/SMES
    • TABLE 146 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 10.7 STARTUP/SME EVALUATION MATRIX
    • 10.7.1 PROGRESSIVE COMPANIES
    • 10.7.2 RESPONSIVE COMPANIES
    • 10.7.3 DYNAMIC COMPANIES
    • 10.7.4 STARTING BLOCKS
    • FIGURE 38 STARTUP/SME EVALUATION QUADRANT: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET
  • 10.8 COMPETITIVE SCENARIO
    • 10.8.1 DEALS
    • TABLE 147 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DEALS, 2019-2023
    • 10.8.2 OTHER DEVELOPMENTS
    • TABLE 148 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: EXPANSIONS AND INVESTMENTS, 2019-2023

11 COMPANY PROFILES

  • (Business overview, Products/Solutions/Services offered, Recent Developments, MNM view)**
  • 11.1 MAJOR PLAYERS
    • 11.1.1 LIVENT CORPORATION
    • TABLE 149 LIVENT CORPORATION: COMPANY OVERVIEW
    • FIGURE 39 LIVENT CORPORATION: COMPANY SNAPSHOT
    • TABLE 150 LIVENT CORPORATION: PRODUCTS OFFERED
    • TABLE 151 LIVENT CORPORATION: DEALS
    • 11.1.2 ALBEMARLE CORPORATION
    • TABLE 152 ALBEMARLE CORPORATION: COMPANY OVERVIEW
    • FIGURE 40 ALBEMARLE CORPORATION: COMPANY SNAPSHOT
    • TABLE 153 ALBEMARLE CORPORATION: PRODUCTS OFFERED
    • TABLE 154 ALBEMARLE CORPORATION: OTHERS
    • 11.1.3 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.
    • TABLE 155 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
    • FIGURE 41 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
    • TABLE 156 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
    • 11.1.4 AMERICAN ELEMENTS
    • TABLE 157 AMERICAN ELEMENTS: COMPANY OVERVIEW
    • TABLE 158 AMERICAN ELEMENTS: PRODUCTS OFFERED
    • 11.1.5 GLOBE QUIMICA
    • TABLE 159 GLOBE QUIMICA: COMPANY OVERVIEW
    • TABLE 160 GLOBE QUIMICA: PRODUCTS OFFERED
    • 11.1.6 JIANGSU NHWA PHARMACEUTICAL CO., LTD.
    • TABLE 161 JIANGSU NHWA PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
    • TABLE 162 JIANGSU NHWA PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
    • 11.1.7 PANCHSHEEL ORGANICS LTD (POLTD)
    • TABLE 163 PANCHSHEEL ORGANICS LTD (POLTD): COMPANY OVERVIEW
    • FIGURE 42 PANCHSHEEL ORGANICS LTD (POLTD): COMPANY SNAPSHOT
    • TABLE 164 PANCHSHEEL ORGANICS LTD (POLTD): PRODUCTS OFFERED
    • 11.1.8 BLANVER
    • TABLE 165 BLANVER: COMPANY OVERVIEW
    • TABLE 166 BLANVER: PRODUCTS OFFERED
  • 11.2 OTHER PLAYERS
    • 11.2.1 ZHENJIANG POWORKS CO., LTD.
    • TABLE 167 ZHENJIANG POWORKS CO., LTD.: COMPANY OVERVIEW
    • 11.2.2 AXIOM CHEMICALS PVT. LTD.
    • TABLE 168 AXIOM CHEMICALS PVT. LTD.: COMPANY OVERVIEW
    • 11.2.3 HUBEI RISON CHEMICAL CO., LTD.
    • TABLE 169 HUBEI RISON CHEMICAL CO., LTD.: COMPANY OVERVIEW
    • 11.2.4 PHARMAFFILIATES ANALYTICS AND SYNTHETICS P. LTD.
    • TABLE 170 PHARMAFFILIATES ANALYTICS AND SYNTHETICS P. LTD.: COMPANY OVERVIEW
  • *Details on Business overview, Products/Solutions/Services offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS